Legal & General Group PLC Medicinova Inc Transaction History

Legal & General Group PLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 12, 2021	SELL	$3.76 - $5.14 $18,126 - $24,779	-4,821 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$4.81 - $8.74 $1,212 - $2,202	-252 Reduced 4.97%	4,821 $24,000
Q3 2020 Nov 13, 2020	SELL	$4.67 - $11.0 $9,372 - $22,077	-2,007 Reduced 28.35%	5,073 $27,000
Q2 2020 Aug 14, 2020	SELL	$3.06 - $7.06 $296 - $684	-97 Reduced 1.35%	7,080 $38,000
Q1 2020 May 14, 2020	SELL	$2.9 - $6.97 $5,011 - $12,044	-1,728 Reduced 19.4%	7,177 $27,000
Q4 2019 Feb 13, 2020	BUY	$6.48 - $8.76 $10,776 - $14,567	1,663 Added 22.96%	8,905 $60,000
Q2 2019 Aug 14, 2019	BUY	$8.29 - $13.22 $7,046 - $11,237	850 Added 13.3%	7,242 $70,000
Q4 2018 Feb 15, 2019	BUY	$7.65 - $12.83 $5,936 - $9,956	776 Added 13.82%	6,392 $52,000
Q3 2018 Nov 20, 2018	SELL	$7.06 - $12.49 $5,111 - $9,042	-724 Reduced 11.42%	5,616 $70,000
Q2 2018 Aug 10, 2018	SELL	$7.96 - $13.23 $4,043 - $6,720	-508 Reduced 7.42%	6,340 $50,000
Q1 2018 May 17, 2018	SELL	$6.6 - $13.91 $4,983 - $10,502	-755 Reduced 9.93%	6,848 $70,000
Q4 2017 Feb 13, 2018	BUY	$5.89 - $7.21 $44,781 - $54,817	7,603	7,603 $49,000

4.83M

9.4K

Ticker MNOV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,046,200
Market Cap $113M
Description
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and ...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.